Influenza viruses cause annual epidemics and occasional pandemics of respiratory tract
infections that produce a wide spectrum of clinical disease severity in humans. The novel …

With the expanding use of molecular assays, viral pathogens are increasingly recognized
among critically ill adult patients with community-acquired severe respiratory illness; studies …

Background Neuraminidase inhibitors were widely used during the 2009–10 influenza A
H1N1 pandemic, but evidence for their effectiveness in reducing mortality is uncertain. We …

Background The first identified cases of avian influenza A (H7N9) virus infection in humans
occurred in China during February and March 2013. We analyzed data obtained from field …

Effective antivirals provide crucial benefits during the early phase of an influenza pandemic,
when vaccines are still being developed and manufactured. Currently, two classes of viral …

Summary Background The Middle East respiratory syndrome coronavirus (MERS-CoV) has
been reported to have a high case-fatality rate. Currently, there is no specific therapy or …

Abstract In late December 2019 in Wuhan, China, several patients with viral pneumonia
were identified as 2019 novel coronavirus (2019‐nCoV). So far, there are no specific …

Current influenza antivirals have limitations with regard to their effectiveness and the
potential emergence of resistance. Encouragingly, several new compounds which inhibit the …

Estimating the case-fatality risk (CFR)—the probability that a person dies from an infection
given that they are a case—is a high priority in epidemiologic investigation of newly …

Background. Neuraminidase inhibitor (NAI) antiviral drugs can shorten the duration of
uncomplicated influenza when administered early (< 48 hours after illness onset) to …